Ocular Therapeutix (OCUL) PT Raised to $11 at Raymond James

Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval

Cantor Fitzgerald analyst Elemer Piros raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $24.00 (from $22.00) while maintaining an Overweight rating following the DEXTENZA approval.

Piros commented, "This morning Ocular Therapeutix held a conference call and announced that DEXTENZA 0.4mg... More

Pre-Open Movers 12/03: (TSRO) (GBT) (NBEV) Higher; (OCUL) (BLUE) (GSK) Lower (more...)

Pre-Open Movers

TESARO Inc (NASDAQ: TSRO) 59% HIGHER; GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction significantly strengthens GSKs pharmaceutical business, accelerating the build of GSKs pipeline and commercial capability in oncology.

Global Blood Therapeutics, Inc. (Nasdaq: GBT)... More

Ocular Therapeutix (OCUL) to Resume Trading at 7:30 am ET

Ocular Therapeutix (NASDAQ: OCUL) to Resume Trading at 7:30 am ET

Ocular Therapeutix (OCUL) Announces FDA Approval of DEXTENZA for Treatment of Ocular Pain

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery.

We are extremely pleased to announce the approval of DEXTENZA, coming so soon after our pre-approval inspection and... More